Individuals with subtotal complement C6 deficiency possess a C6 molecule that is 14% shorter than normal C6 and present in low but detectable concentrations (1-2% of the normal mean). We now show that this dysmorphic C6 is bactericidally active and lacks an epitope that was mapped to the most carboxy-terminal part of C6 using C6 cDNA fragments expressed as fusion proteins in the pUEX expression system. We thus predicted that the abnormal C6 molecule might be carboxy-terminally truncated and sought a mutation in an area -14% from the carboxy-terminal end of the coding sequence. By sequencing PCR-amplified products from this region, we found, in three individuals from two families, a mutation that might plausibly be responsible for the defect. All three have an abnormal 5' splice donor site of intron 15, which would probably prevent splicing. An in-frame stop codon is found 17 codons downstream from the intron boundary, which would lead to a truncated polypeptide 13.5% smaller than normal C6. This result was unexpected, as earlier studies mapped the C5b binding site, or a putative enzymatic region, to this part of C6. Interestingly, all three subjects were probably heterozygous for both subtotal C6 and complete C6 deficiency. (J. Clin. Invest. 1995. 95:1877-1883.) Key words: antigenic determinants complement membrane attack complex * immunologic diseases -meningococcal infections * RNA splicing
Introduction
The sixth component of human complement (C6) is part of the terminal complement cascade that is activated via either the classical or the alternative pathways of complement. Following activation, C6 is incorporated into the terminal complement complex, which, as membrane attack complex, is capable of membrane disruption and cell lysis when formed on the cell membrane (1, 2) .
Some individuals with inherited C6 deficiency who ap-thermore, hemolytically active but structurally abnormal, as it was 14% smaller than normal C6 (4) . This condition has been designated subtotal C6 deficiency (C6SD). In contrast, the majority of C6-deficient individuals investigated by sensitive hemolytic assays and ELISA were found to completely lack C6 functional and antigenic activity (3, 4) and have been designated "quantitatively zero C6 deficient" (C6QO [4] ).
The eight C6SD individuals from four families investigated so far all appear to express the same dysmorphic molecule and thus may well have the same molecular defect. The dysmorphic C6 show the same abnormal isoelectric focusing pattern, a strong indicator of identity (4) . The protein is also indistinguishable (4) from that expressed in the two families with combined subtotal deficiency of C6 and C7 (5, 6) . Furthermore, in contrast to individuals with C6QO, C6SD subjects do not appear to be more susceptible to Neisserial infections than the population at large (4) .
Even though the molecular bases of other terminal complement deficiencies were investigated only recently (7) (8) (9) , the characterization of every mutation in the genes responsible for the deficiencies will not necessarily yield fundamental new information. In this instance, however, a dysmorphic molecule that is still functionally active is secreted in measurable amounts. Thus, the determination of the molecular basis of C6SD should yield important ex vivo-derived information about the regions of C6 that appear to be less essential for membrane attack assembly.
Since the mAb WU 6-4 reacted with this 14% shorter molecule (3), we initially tried to map its epitope in normal C6 using an expression system. A second commercially available mAb was also used. Epitope mapping was expected to help with excluding gene regions or even with localizing the most likely regions for the mutation to avoid sequencing the whole gene.
Methods
Individuals. DNA was obtained from three C6SD subjects (from two families) who have been reported previously. The code used to identify the affected subjects refers to their places in their respective family trees as detailed (4) . The South African Cape Coloured family A was ascertained because of complement screening of an 11-yr-old child with 1. Abbreviations used in this paper: C6SD, subtotal C6 deficiency; C6QO, quantitatively zero C6 deficiency; GTB, gelatin-Triton-benzamidine; NHS, normal human serum; TCC, terminal complement complex; YT, yeast tryptone. poststreptococcal nephritis. The Cape Coloured family B was ascertained because a child was C6Q0 and suffered meningococcal infection (B 111-1). On screening the C6 in family members, her mother (B II-2) was found to be C6SD (4).
Buffers. PBS: 9 mM phosphate buffer, pH 7.2, containing 140 mM sodium chloride, Tris-boric acid-EDTA, containing 90 mM Tris, 90 mM boric acid, and 2.5 mM EDTA; PBS-gelatin-Triton-benzamidine (GTB), PBS supplemented with 0.25% (wtlvol) gelatin, 0.1% (vol/vol) Triton X-100, and 1 mM benzamidine.
Antibodies. Monospecific polyclonal IgG directed against C6 and C7 were raised in goats (GaC6, GaC7) by standard methods (10) . The mAb WU 6-4 was generated in Balb/c mice as detailed (10) . Another murine mAb anti-C6 was obtained from Quidel (San Diego, CA) and is termed QaC6. Biotinylation was performed according to standard protocols (1 1).
C6 ELISA and SDS-PAGE analysis. For the C6 ELISA either WU 6-4 or QaC6 were used as coating antibodies together with biotinylated GaC6 as detection antibody (3) . SDS-PAGE analysis of 100 ng purified C6 or C7 (both from Cytotech, San Diego, CA) was performed using both mAbs as described (4) .
Assessment ofbactericidal activity. Neisseria meningitidis serogroup B organisms were initially grown for 6 h in Muller-Hinton broth at 37°C and at -150 rpm, until they reached log phase. For the killing experiments each tube contained 4.5-9 x 104 bacteria in HBSS (Oxoid, Basingstoke, UK) with 0.1I% gelatin adJed. Tubes for determining normal C6 bactericidal activity also contained aliquots of normal human serum (NHS) (range 0.02 1.l-10 bd) made up to 10 j1i with human C6QO serum. The test samples also contained aliquots of C6SD serum (from subject A 11-1) in the range 0.04 pil-25 1.I serum diluted in (or added to a minimum of 10 [l) C6QO serum. Samples were made up to 500 A1 with HBSS gelatin. Controls were as above with (i) no serum added or (ii) 10 ,ul C6QO serum added. Samples were incubated at 37°C for 20 min at 150 rpm. Appropriate dilutions from all tubes were made in Muller-Hinton broth and plated on chocolate agar plates. Plates were incubated at 37°C in 5% C02, and the colonies were counted the following day. Bactericidal killing, relative to the controls with no serum added, was calculated for each tube. The lowest serum dilution producing at least 80% bactericidal killing was determined. C6 levels in the NHS and the C6SD serum were determined by ELISA, and the difference in molecular weight was taken into account in calculating the number of C6 molecules present. Efficiency of killing of C6SD was calculated as the ratio between the numbers of normal C6 and C6SD molecules producing 80% bactericidal killing.
Restriction For preparative purposes 0.8 or 1.6% low melting point agarose (Gibco BRL) gels were used. The band of interest was excised and DNA was extracted from the molten agarose (12) .
Construction of C6 cDNA libraries for epitope mapping. To characterize the epitopes of the mAbs anti-C6, an epitope mapping method was used that was modified from Stanley and Luzio (13) and Stanley and Herz (14) The three subtypes of the expression vector pUEX-pUEX 1, 2, and 3-were used to generate expression in all three reading frames (17) . They carry promotors of phage X as well as the c1857 gene encoding a heat-sensitive repressor (17) and enable expression of proteinspecific cDNA as fusion protein with /3-galactosidase. Vector-transformed cells grow at 30'C on yeast tryptone (YT) plates containing 50 jig/ml ampicillin (YT-A). The vectors were kindly donated by Dr. J. P.
Luzio (Cambridge University, Cambridge, UK) and prepared from the host Escherichia coli strain MC 1061 (18) by the alkaline lysis method (12) . Purified plasmids were cleaved within the polylinker using SmaI and dephosphorylated. An approximately twofold molar excess of endrepaired C6 cDNA fragments (1-20 ng) was ligated into 20 ng SmaI cut vector (pUEX 1, 2, or 3) overnight at 15'C including controls (12) .
The host E. coli strain MC 1061, which grows in YT medium at 370C, was made competent using CaCl2 (12) . 200 Protein synthesis (expression) was induced in the colonies on the nitrocellulose membranes at 42°C for 2 h. The colonies were then lysed in 5% SDS at 700C for 30 min, and the generated fusion proteins were further fixed to the nitrocellulose by electrotransfer (19) . After the blotting, the nitrocellulose membranes were incubated with PBS-GTB in four steps for 10 min each and DNAse treated, and further bacterial debris was removed. Washing steps (with PBS-GTB) were incorporated between each of the following steps.
The membranes were incubated with 100 jig biotinylated or unbiotinylated antibody diluted in 10 ml PBS-GTB for at least 2 h at 4°C. All antibody preparations were supplemented with E. coli protein (0.5-2 mg/ml; preparation modified from Sambrook et al. [12] ) to minimize reaction of antibodies towards the E. coli proteins on the nitrocellulose. The blots were developed using streptavidin horseradish peroxidase or horseradish peroxidase-labeled goat anti-mouse IgG (both from DAKO, Glostrup, Denmark), respectively, at 1/500 dilutions (in PBS-GTB, for at least 2 h) followed by addition of the peroxidase substrate 4-chloro-l-naphtol (Sigma Chemical Co., Poole, UK; 30 mg dissolved in 10 ml methanol, diluted into 50 ml triethanolamine buffered saline) supplemented with 0.01% (vollvol) H202.
Positive colonies were selected from the original master plate. One aliquot of these cells was expressed again. Another aliquot was processed by the alkaline lysis method (12 Instruments, Norwalk, CT) as follows: denaturation at 940C for 1 min, annealing at 560C for 1 min, and extension at 720C for 3 min. In the first cycle denaturation was extended to 3 min. The amplified products were separated and excised from low melting point agarose gels, cleaved by EcoRI, and ligated into the EcoRI site of M13mp8, and individual clones were sequenced by the dideoxy chain termination method (23) . The sequence was read in both directions in a number of independent clones and compared with published cDNA (15, 24) or genomic DNA sequences (21) .
In some instances the C6 exon 15 PCR product was gel purified and then directly sequenced from both ends using the Circumvent thermal cycle sequencing kit (New England Biolabs) and y32P-labeled primers #23a and #24.
Results
Assessment of bactericidal activity of the C6 from C6SD subjects. The bactericidal experiments were done on two occasions with C6SD serum from subject A II-1. The specific efficiency of bactericidal killing ranged between 0.1 (10% of normal) and 0.35 (35% of normal). Serum from a combined C6SD/C7SD subject (5) was also analyzed twice and found to have comparable bactericidal activity, whereas no killing was observed in the C6QO serum alone. The range of the efficiencies determined was high because of the very low absolute values of protein concentration and activity, but the results clearly demonstrated that positive bactericidal activity was mediated by the C6SD protein and that the efficiency was reduced compared to normal C6.
Presence ofepitopes ofmAbs anti-C6 on the C6from C6SD subjects. In contrast to the ELISA based on WU 6-4, the ELISA using QaC6 as coating antibody in the otherwise identical ELISA setup produced only background optical densities, not only for C6QO but also for C6SD samples (Fig. 1) . When the optical densities were calculated, the reaction of QaC6 to the C6 of C6SD samples was < 4% when compared to WU 6-4. The values for C6QO and C6SD samples were even indistinguishable in the QaC6 ELISA. This strongly suggests that the epitope of this mAb is not present on the shorter C6, although it cannot be fully excluded that the epitope is present but that the three-dimensional conformation of the dysmorphic molecule simply prevents access of the mAb to it.
Presence of epitopes of mAbs anti-C6 on normal C6 after SDS-PAGE and immunoblotting. To ascertain whether the C6 epitopes of both mAbs were still available after SDS treatment, purified C6 or C7 were subjected to SDS-PAGE followed by immunoblotting. When WU 6-4 or GaC6 were used for detection, two C6 bands at 98 kD and 69 kD were detected in each of the C6 tracks; QaC6 only reacted with the band at 98 kD. No cross-reaction to C7 was observed.
Mapping of the epitopes of mAbs anti-C6 to different parts ofC6. All three end-filled C6 cDNA fragments were ligated into pUEX 1, 2, and 3 and expressed in MC 1061. Using biotinylated GaC6, expressed protein was recognized when the appropriate vectors were used (with a few exceptions): C6-a-or C6-f3- was seen in samples from all four C6SD subjects (four families) tested in the ELISA using WU 6-4 as coating antibody. In contrast, no substrate turnover was seen in any of these samples using QaC6 as coating antibody, although this mAb seems to react more strongly with the C6 of NHS.
whereas C6-PVX-derived proteins were detected in pUEX 1 (more than 50 colonies each). C6 protein-expressing colonies were induced and developed again; a weak staining was observed with the GaC6 and strong stainings were observed in the combinations QaC6 with C6-f3 and WU 6-4 with C6-a (Fig. 2) . Positive colonies were analyzed by alkaline lysis and digestion with NdeI, which confirmed the expected insert sizes.
Mapping of the epitope of QaC6 to the carboxy-terminal end of C6. To map the epitope of QaC6 within C6-3, aliquots of the latter (200 ng each) were digested using three different restriction enzymes: Alul, DdeI, and BspMI (Fig. 3) After expression and development using QaC6, most of the positive colonies (> 95%) using AluI-cleaved C6-P were in pUEX 3 as expected. The expression of DdeI-cleaved fragments yielded 30% positive colonies with pUEX 3, and 61% positive colonies with pUEX 1, the predicted vector for the carboxyterminal fragment. The expression of BspMI-cleaved C6-,6
yielded < 3% with pUEX 3, and 94% positive colonies with pUEX 1, the predicted vector for the carboxy-terminal fragment. This carboxy-terminal fragment consists of the 65 most carboxy-terminally located amino acid residues of C6, amounting to 7% of the C6 molecule (Fig. 3) . 31 positive colonies (at least 9 for each restriction enzyme) were selected from the plates and expressed again; all were positive with GaC6. 10 of these colonies (at least 3 for each restriction enzyme) were analyzed twice by alkaline lysis and digestion with NdeI. The sizes of the inserts from the positive colonies were within 10% of the expected sizes for the carboxyterminal fragments. Inserts from 7 GaC6-positive but QaC6-negative colonies from the digestion with BspMl were also sized and found to be of the size of the amino-terminal fragment. All inserts were cleaved with the three restriction enzymes, which confirmed that the positive colonies contained the respective carboxy-terminal fragment, whereas the negative colonies contained the respective amino-terminal fragment. Thus, the epitope of QaC6 is most likely present within the most carboxyterminal part of C6.
Characterization of the molecular basis of the subtotal C6 terminus. This corresponds in the gene to the region of the small exon 15, which is closely flanked by EcoRI sites (21, Fig. 3 ). Amplification of exon 15 sequence was performed by PCR using genomic DNA of two normal subjects and three C6SD subjects (from two unrelated families). A PCR product of appropriate size comparable to the predicted length of 386 bp was detected after amplification of DNA in all cases. The EcoRI digested product, which covers 88.5% of the sequence between both primers, was also comparable to the predicted length of 299 bp.
EcoRI fragment-derived sequence was obtained from 10 informative clones from the two C6 normal subjects and from 20 informative clones derived from the three C6SD subjects. All sequences from the clones of the former but only 14 from the clones of the latter were identical (Table I) to the published C6 genomic sequence (21) . The other 6 sequences (at least 1 for each subject or 2 for each family) were identical among themselves and showed a mutation at the 5' splice donor site of intron 15, changing the sequence from AG/gt to AG/gc (Fig.  4) . Uncleaved PCR product-derived sequences obtained from a C6SD subject by thermal cycle sequencing also yielded both wild-type sequence and 5' splice donor mutation. This mutation was the only difference from the wild-type sequence and was found in the area predicted from results obtained at the protein level.
A PCR product from the completely C6-deficient subject, who is the son (B 11-3) of one of the C6SD subjects (B 11-1), was also sequenced directly by thermal cycle sequencing in both directions. Both sequences were entirely of wild type, suggesting that the C6Q0 defect lies elsewhere.
Discussion
The molecular pathologies responsible for complete deficiencies of C6 have not been reported, and those responsible for subtotal deficiency of C6, either alone or in combination with subtotal C7 deficiency, have been investigated in parallel and reported in abstract only (25, 26) . Both types of deficiencies were pre--viously expected to be caused by a point mutation or other small defect rather than a deletion, as Southern blot analyses of DNA from a number of C6-deficient subjects, including those later characterized as C6SD, have shown normal-sized fragments (27) .
To avoid sequencing the whole genomic DNA of subtotal .M[ Figure 4 . Representative sequencing gel from a C6SD subject (3'->5' orientation). Amplified DNA clones from normal individuals always showed the wild type (W), whereas in clones from C6SD subjects both wild type (W) and a mutated form (A{) were detected (see Table I ). The sequence depicted is from parts of exon 15 and intron 15 (21) : AGAAGAAGACTGTAG/ g~aagagataccc; wild type: AG/gt.
C6-deficient subjects, we sought some preliminary information about the location of the defect by mapping the epitopes of two mAbs, one of which was previously shown to react with the abnormal C6 (3) . Using the pUEX expression system, the epitope of this mAb (WU 6-4) was mapped within the middle of the coding region of C6. In contrast, QaC6 failed to bind to the dysmorphic C6, implying that its epitope might be missing in the dysmorphic molecule. Its epitope was mapped to the most carboxy-terminal 7% of the C6 coding sequence. As the dysmorphic molecule is 14% shorter than normal C6, we concluded that the C6 of C6SD subjects is very probably carboxy-terminally truncated by 14%. This is supported by SDS-PAGE data, because the lower C6 band at 69 kD that was not detected by QaC6 possibly represents the 70 kD tryptic cleavage product of C6, consisting of the amino-terminal two-thirds of C6 (15, 24) . The molecular basis of C6SD was therefore sought in a region at which 86% of amino acid residues were amino terminal and 14% carboxy terminal. Analysis of sequencing data obtained from three subtotal C6-deficient subjects revealed a mutation at the 5' splice donor site of intron 15. This mutation was found in all three subtotal C6-deficient subjects but only in 6 out of 20 of their clones, which can be explained by the heterozygosity of these subjects. This was confirmed by Circumvent thermal cycle sequencing (New England Biolabs). Previously, it had been shown that one of these subjects (B 11-2) , although subtotal C6 deficient, has two complete C6-deficient offspring, indicating that she carries a C6QO gene in addition to the C6SD gene (4) . The finding that the C6QO offspring was homozygous for the wild type indicates that the normal sequence data detected in the C6SD subject were obtained from the DNA strand containing the C6QO gene, which presumably has a mutation in a different area. Recent data indicate that the two types of C6 deficiency occur on different haplotype backgrounds (28, 29). Heterozygosity for two different types of C6 deficiency also seemed likely for the other two subjects (A TI-1 and A II-3) investigated (28, depicted as members of family 2 in that publication).
The mutation found would very probably prevent splicing out of intron 15 (30) . Intronic sequences would thus be translated, creating one codon altered at the boundary and 17 novel amino acids up to a termination codon in phase with the reading Assuming that the mutation behaves as predicted and that the lack of reactivity with QaC6 is due to premature termination of the polypeptide, the lack of the carboxy-terminal one-seventh of the C6 molecule still permits functional activity. The missing part, which corresponds to the carboxy-terminal third of the first Factor I module and the entire second Factor I module of C6 (15, 24) , has to be considered to be of apparently minor functional importance for TCC assembly. However, these modules have been thought to be responsible for binding to C5 when in vitro binding studies were performed (31) . Other investigators stressed the importance of the short consensus repeats (SCRs) for binding of C6 to C5 (24, 32) , as SCRs have also been shown to bind specifically to the C5b homologues C3b and C4b (33) , suggesting an evolutionarily conserved mechanism. Nakano et al. (32) claimed the existence of an enzymatic moiety of C6 and mapped it to the two serine-rich sequences of the complement control Factor I module 2 of C6. Any such moiety will be lost in the functionally active C6 of C6SD subjects and thus is unlikely be of importance for hemolytic activity.
The question of whether or not the C6 concentration and its functional potency have any significant impact on host defense arises. It seems likely that they do since a local enrichment should be achievable (34, 35) , only small amounts of complement are needed for marked hemolytic activity (3, 36) , and sublytic concentrations of complement exert a wide range of important biological functions (37 (4) , and we now report the use of a sensitive assay that showed that the protein is also bactericidally active, although it is less efficient than normal C6. Bactericidal activity was not detected in another C6SD in a previous report (3), possibly because of the much higher concentration of bacteria (E. coli) used, which could mask functional C6SD activity.
Demonstrating bactericidal activity against gram-negative bacteria is important not only because it is clinically relevant, but also because the process is more complex than the production of hemolysis (39) . Thus, it can be concluded that the abnormal C6 is only slightly less functionally active than normal C6 (less than an order of magnitude). In addition, the only moderately impaired functional activity implies that the carboxy-terminal part of C6 cannot represent the C5b binding site.
None of the C6SD subjects reported here have suffered Neisserial disease, and there is no evidence that they are any more susceptible than C6-sufficient subjects. Some come from families in which family members who are totally C6 deficient were ascertained by their history of meningococcal infection. Thus, we may assume that the C6SD subjects in these families were exposed to meningococci but did not become ill, perhaps because their very small amount of C6 protected them. If this assumption is true, C6SD subjects will be less likely to be identified than C6QO patients, who were ascertained because of meningococcal disease either in themselves or in a sibling (40, 41) .
Both C6 and C7 allotyping have proven to be useful for tracing of carriers in families with affected subjects (42) , as the structural genes for C6 and C7 are linked (43, 44) . These assays may now be complemented by molecular markers that are able to detect the mutation itself, not only in suspected family members but also in the population at large. This will facilitate further investigations into the susceptibility of C6SD subjects to disease.
In summary, the probable molecular basis of the subtotal C6 deficiency has been determined, as a plausible mutation was found in an area predicted from SDS-PAGE molecular weight estimation and mAb epitope mapping. The translated molecule, present in low amounts, was characterized as carboxy-terminally truncated but functionally active, which is surprising as the missing region was thought to be important for functional activity.
